Orgenesis Inc. (ORGS)
NASDAQ: ORGS · IEX Real-Time Price · USD
0.507
-0.006 (-1.13%)
At close: Apr 26, 2024, 4:00 PM
0.512
+0.005 (0.97%)
After-hours: Apr 26, 2024, 6:00 PM EDT
Orgenesis Revenue
In the year 2023, Orgenesis had annual revenue of $530.00K, a decrease of -98.53%. Revenue in the quarter ending December 31, 2023 was $165.00K, a -98.79% decrease year-over-year.
Revenue (ttm)
$530.00K
Revenue Growth
-98.53%
P/S Ratio
32.86
Revenue / Employee
$3,630
Employees
146
Market Cap
17.41M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 530.00K | -35.50M | -98.53% |
Dec 31, 2022 | 36.03M | 523.00K | 1.47% |
Dec 31, 2021 | 35.50M | 27.85M | 363.96% |
Dec 31, 2020 | 7.65M | 3.75M | 96.26% |
Dec 31, 2019 | 3.90M | -14.76M | -79.10% |
Nov 30, 2018 | 18.66M | 8.57M | 84.90% |
Nov 30, 2017 | 10.09M | 3.69M | 57.71% |
Nov 30, 2016 | 6.40M | 3.42M | 115.10% |
Nov 30, 2015 | 2.97M | - | - |
Nov 30, 2014 | 0 | - | - |
Nov 30, 2013 | 0 | - | - |
Nov 30, 2012 | 0 | - | - |
Nov 30, 2011 | 0 | - | - |
Nov 30, 2010 | 0 | - | - |
Nov 30, 2009 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ATI Physical Therapy | 699.02M |
CareCloud | 117.06M |
VBI Vaccines | 8.68M |
PAVmed | 2.45M |
Akso Health Group | 2.20M |
Talis Biomedical | 2.13M |
Benitec Biopharma | 61.00K |
ORGS News
- 11 days ago - Orgenesis Provides Year End Business Update - GlobeNewsWire
- 17 days ago - Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility - GlobeNewsWire
- 5 weeks ago - Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference - GlobeNewsWire
- 6 weeks ago - Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes - GlobeNewsWire
- 7 weeks ago - Orgenesis Inc. Announces $2.3 Million Private Placement - GlobeNewsWire
- 2 months ago - Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing - GlobeNewsWire
- 3 months ago - Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic - GlobeNewsWire
- 5 months ago - Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM - GlobeNewsWire